A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and
activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk
factors.